Top Industry Leaders in the Central Nervous System Biomarkers Market
Latest Central Nervous System Biomarkers Companies Updates:
Eisai Co., Ltd. and Biogen Inc. (US): Presented research at a recent conference exploring the use of plasma-based biomarkers in the Phase 3 AHEAD 3-45 study of lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for Alzheimer's disease. This highlights the ongoing focus on blood-based biomarkers for easier and less invasive testing.
Diadem (US): Published clinical data showing its AlzoSure biomarker test can predict the progression of Alzheimer's disease years before symptoms appear. This breakthrough offers potential for early intervention and personalized treatment strategies.
Roche (Switzerland): Announced FDA approval for its Elecsys® Neuro kit for measuring tau protein in cerebrospinal fluid, aiding in the diagnosis of Alzheimer's disease and other neurodegenerative conditions.
Lumosity (US): Partnered with the University of California, San Francisco (UCSF) to develop and validate novel digital cognitive assessments and biomarkers for early detection of
Alzheimer's disease. This collaboration combines traditional research with digital health approaches.
Quanterix Corporation (US): Showcased its Simoa® technology platform at a medical conference, highlighting its potential for ultrasensitive detection of various CNS biomarkers, including tau and synuclein alpha, for early diagnosis of neurodegenerative diseases.
List of Central Nervous System Biomarkers Key companies in the market:
- Thermo Fisher Scientific (US)
- Merck & Co. (US)
- AbaStarMDx Inc. (US)
- Abiant, Inc. (US)
- Avacta Group plc (UK)
- Diagenic Asa (Norway)
- Banyan Biomarkers (US)
- Avid Radiopharmaceuticals Inc. (US)
- Acumen pharmaceuticals Inc. (US)